Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Inv. presentation
Director departure
Paratek Pharmaceuticals, Inc. (PRTK) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/11/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/07/2023 8-K Acquisition/merger/asset purchase announced
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Agreement and Plan of Merger, by and among the Company, Resistance Acquisition, Inc. and Resistance Merger Sub, Inc",
"Form of Contingent Value Rights Agreement to be entered into between Resistance Acquisition, Inc. and a Rights Agent",
"Form of Voting Agreement to be entered into between Parent and the Management Stockholders",
"Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings"
03/14/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year  Interactive Data
Docs: "EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS OF PARATEK PHARMACEUTICALS, INC."
06/09/2022 8-K Quarterly results
09/27/2021 8-K Quarterly results
07/14/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
06/14/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
01/04/2021 8-K Quarterly results
06/12/2020 8-K Submission of Matters to a Vote of Security Holders
02/25/2020 8-K Quarterly results
12/18/2019 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Total award valued at up to $285 million - Paratek to host a conference call today, December 18, 2019 at 5:30 p.m. EDT BOSTON, December 18, 2019 – Paratek Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced today that the Department of Health and Human Services , Office of the Assistant Secretary for Preparedness and Response , and Biomedical Advanced Research and Development Authority has awarded the Company a 5-year contract, with an option to extend to 10-years, to support the development of Paratek’s NUZYRA® for the treatment of pulmonary anthrax, FDA post-marketing requirements associated with the initial NUZYRA approval, and the option to procure up to 10,000 treatment courses of N..."
06/26/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Paratek Pharmaceuticals Promotes Evan Loh, M.D. to Chief Executive Officer; Michael Bigham to Assume Role of Executive Chairman -Adam Woodrow Promoted to President & Retains Chief Commercial Officer Position"
06/12/2019 8-K Submission of Matters to a Vote of Security Holders
03/18/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Consulting Agreement between the Company and Douglas Pagán",
"Paratek Pharmaceuticals Announces Management Change"
02/27/2019 8-K Quarterly results
02/27/2019 8-K Quarterly results
01/04/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Paratek Pharmaceuticals, Inc. presentation for 37th Annual J.P. Morgan Healthcare Conference"
12/03/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Paratek Pharmaceuticals Files Two Patent Term Extensions in the United States; Expects NUZYRA TM Patent Protection Exclusivity Until at Least October 2030"
11/06/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Paratek Pharmaceuticals, Inc. presentation for earnings call for the quarter ended September 30, 2018"
10/23/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Paratek Pharmaceuticals, Inc. presentation for 2018 Paratek Investor Day"
10/18/2018 8-K Quarterly results
10/04/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Revenue Performance Incentive Plan",
"Form of Award Agreement under the Revenue Performance Incentive Plan",
"Paratek Announces Acceptance of European Marketing Authorization Application for Oral and Intravenous Omadacycline"
10/02/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Paratek Announces FDA Approval of NUZYRA™ – Modernized Tetracycline for the Treatment of Community-Acquired Bacterial Pneumonia and Acute Skin and Skin Structure Infections specifically designed to overcome tetracycline resistance –"
08/08/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "FDA Advisory Committee Recommends Approval of Paratek’s Omadacycline"
06/18/2018 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Docs: "Paratek Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan"
04/23/2018 8-K Quarterly results
04/18/2018 8-K Results of Operations and Financial Condition
04/13/2018 8-K Resignation/termination of a director
Docs: "Paratek Appoints Rolf K. Hoffman to Company’s Board of Directors"
03/01/2018 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Remains on Track for Commercial Launch by First Quarter 2019"
01/19/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement, between Paratek Pharmaceuticals, Inc. and BTIG, LLC",
"Opinion of Ropes & Gray LLP"
01/05/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Paratek Pharmaceuticals, Inc. presentation for 36th Annual J.P. Morgan Healthcare Conference"
08/04/2017 8-K Quarterly results
07/17/2017 8-K Form 8-K - Current report:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy